Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.

Nature - 24 Mar 2011

Bivona Trever G, Hieronymus Haley, Parker Joel, Chang Kenneth, Taron Miquel, Rosell Rafael, Moonsamy Philicia, Dahlman Kimberly, Miller Vincent A, Costa Carlota, Hannon Gregory, Sawyers Charles L

Abstract excerpt

Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFR tyrosine kinase inhibitors (TKIs), but the magnitude of tumour regression is variable and transient. This heterogeneity in treatment response could result from genetic modifiers that regulate the degree to which tumour cells are dependent on mutant EGFR. Through a pooled RNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down-Regulation
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to fas Receptor

Share to Genes, erbB-1

Share to I-kappa B Proteins

Share to Mutant Proteins

Share to NF-kappa B

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 21430781
DOI: 10.1038/nature09870
PMCID: PMC3541675

Genes

EGFR
FAS
CFLAR
IKBKB
NFKBIA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.PMID 21430781Read ↗

Genetic disruption of oncogenic Kras sensitizes lung cancer cells to Fas receptor-mediated apoptosis.Semantic proximity Read ↗

FLIP is essential for oncogenic <i>KRAS-</i> driven lung cancerSemantic proximity Read ↗

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.Semantic proximity Read ↗

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.Semantic proximity Read ↗

Regulation of autophagy, NF-κB signaling, and cell viability by miR-124 in KRAS mutant mesenchymal-like NSCLC cells.Semantic proximity Read ↗

RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.Semantic proximity Read ↗

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.Semantic proximity Read ↗

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors.Semantic proximity Read ↗

E2A selectively regulates TGF-β-induced apoptosis in KRAS-mutant non-small cell lung cancer.Semantic proximity Read ↗

Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch.Semantic proximity Read ↗

IKBKE Is a Substrate of EGFR and a Therapeutic Target in Non-Small Cell Lung Cancer with Activating Mutations of EGFR.Semantic proximity Read ↗

Afatinib restrains K-RAS-driven lung tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.